Minerva Neurosciences is a Burlington, Massachusetts drug developer working on roluperidone, a candidate for schizophrenia. NERV reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 14 | Jefferies | Upgrade | Buy | |
| Apr 15 | Citizens | Initiated | Buy |
Seasonality
How NERV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in NERV in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NERV is in one of them and how their past NERV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NERV in an article yet. Here's the latest on the wider market.
About Minerva Neurosciences
Minerva Neurosciences is a pharmaceutical company based in Burlington, Massachusetts. Its main focus is roluperidone, a drug candidate being developed to treat negative symptoms of schizophrenia. The candidate is still moving through clinical trials and the U.S. regulatory approval process, so it is not yet approved for sale. The company's intended customers are patients with schizophrenia, along with the doctors and healthcare providers who treat them.
- Headquarters
- Burlington, MA
- Founded
- 2007
- Website
- minervaneurosciences.com ↗